A Feasibility Trial of LHRH Agonist Discontinuation in Elderly Prostate Cancer Patients
Summary
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.
Arms & interventions
- BehavioralLHRH Agonist Therapy Discontinuation
The intervention involves \*\*discontinuing LHRH agonist therapy\*\* in elderly prostate cancer patients who have been on long-term androgen deprivation therapy. Participants will be monitored for testosterone recovery and PSA levels over a period of up to 3 years.
Outcome measures
Primary
feasibility of stopping LHRH agonist therapy
Fraction of patients maintaining castrate testosterone levels
Time frame: 12 months after discontinuing LHRH agonist therapy
Secondary
Patient interest in stopping treatment
Time frame: End of enrollment (approximately 3 years after study start)
Medication Impact
Time frame: End of study (approximately 3 years after last participant is enrolled)
Impact on Testosterone Levels (12 months)
Time frame: 12 months after last participant starts study
Impact on Testosterone Levels (36 months)
Time frame: 36 months after last participant starts study
Health Care Savings
Time frame: End of study (approximately 3 years after last participant is enrolled)
Visit Compliance
Time frame: End of study (approximately 3 years after last participant is enrolled)
Eligibility criteria
Study locations (2)
The University of Illinois at Chicago (UIC)
Chicago, Illinois, 60607
UChicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637